Table 2.
Tall-Cell Variant Versus Matched Papillary Thyroid Carcinoma Cases
| Parameter | TCV | Matched PTC | TCV vs. matched PTC |
|---|---|---|---|
| Patients | 278 | 278 | |
| Mean follow-up (months) | 28.0 (26.0–30.0) | 27.3 (25.3–29.3) | p = 0.71 |
| Mean age | 54.3 (52.4–56.2) | 54.4 (52.5–56.3) | p = 0.96 |
| Age ≥45 years | 69.8% (64.5–75.1) | 69.8% (64.5–75.1) | p = 0.99 |
| Male | 25.5% (20.4–30.6) | 25.2 (20.1–30.3) | p = 0.99 |
| Gross extrathyroidal extension | 53.6% (50.6–56.6) | 53.2% (50.2–56.2) | p = 0.99 |
| Mean tumor size (mm) | 25.9 (23.9–27.9) | 27.3 (25.2–29.4) | p = 0.93 |
| Cervical metastases | 39.6% (33.9–45.3) | 39.9% (34.1–45.6) | p = 0.99 |
| Distant metastases | 8.3% (5.0–11.5) | 8.3% (5.0–11.5) | p = 0.99 |
| Adjuvant RAI treatment | 55.0% (49.2–60.8) | 55.0% (49.2–60.8) | p = 0.99 |
Patient and tumor characteristics: TCV and matched PTC cases. Data expressed as mean with 95% confidence interval.